Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.56 |
| ▸ | CACNB1 | Q02641 | 6/20 | 0.56 |
| ▸ | BCL2 | P10415 | 4/20 | 0.48 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958329 | 0.83 | HTR7 (0.55) | BCL2BAK1HTR7LMNAPOLB | |
| SCHEMBL1446676 | 0.81 | LMNA (0.53) | BCL2BAK1HTR7LMNAPOLB | |
| SCHEMBL1446715 | 0.79 | HTR7 (0.51) | BCL2BAK1HTR7LMNAPOLB | |
| SCHEMBL3954643 | 0.79 | CACNA1G (0.55) | BCL2BAK1HTR7LMNAPOLB | |
| SCHEMBL588394 | 0.76 | SIGMAR1 (0.67) | BCL2BAK1HTR7LMNADRD4 | |
| SCHEMBL2116073 | 0.76 | HTR7 (0.53) | BCL2BAK1HTR7BCL2L1ALDH1A1 | |
| SCHEMBL8744976 | 0.75 | KDM4E (0.55) | BCL2BAK1HTR7BCL2L1DRD4 | |
| SCHEMBL29137691 | 0.75 | BCL2 (0.57) | BCL2BAK1HTR7LMNAPOLB | |
| Hydrochloric Acid SCHEMBL587708 | 0.75 | SIGMAR1 (0.65) | BCL2BAK1HTR7LMNADRD4 | |
| SCHEMBL1138135 | 0.75 | HTR7 (0.60) | BCL2BAK1HTR7LMNABCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-10-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | ORAI1, CACNA1D, CACNA1C | CACNA2D1 51/4885CACNA1B 4/4885CACNB1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.